FAS and plasma cell myeloma: In multiple myeloma cells, bortezomib has been shown to activate both the intrinsic apoptotic pathway, involving mitochondrial cytochrome c release and caspase-9, as well as the extrinsic, Fas/caspase-8-dependent apoptotic pathway [14].